New Products and Line Extensions are the Contributing Factors to Growth in the Four Major Cancer Markets.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c29800) has announced the addition of Cancer Therapeutics 2006: to their offering. Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry. Our new report entitled Cancer Therapeutics 2006: Market Dynamics and R&D Trends examines these four major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market. Features of this Report --market analysis by class, cancer type, product, company, and geographic region --sales data from 2000 through Sept 2005 as well as full-year 2005 estimates --profiles of leading products in the four major cancer markets and analysis of their market impact --presentation and analysis of clinical data underscoring success of key therapies --market share data for leading companies and products in the field --SWOT analysis for key products in each market --profiles of key emerging therapies and clinical data supporting development --financial forecasts for the four major cancer markets --133 tables/graphs/diagrams illustrating historical sales data, growth rates Growth Rates The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures. Notes: Remember, historically high growth rates don't always mean a high rate of growth looking into the future. and market share by product, class, therapeutic category, and company, company portfolios, pipelines, clinical efficacy data, as well as epidemiologic data Additionally, Cancer Therapeutics 2006 offers readers a critical examination of emerging and pipeline products in colorectal, prostate, lung, and breast cancer. Pipeline products with the greatest potential are assessed for their clinical efficacy and possible market impact. Briefs are provided for companies that are either firmly entrenched en·trench also in·trench v. en·trenched, en·trench·ing, en·trench·es v.tr. 1. To provide with a trench, especially for the purpose of fortifying or defending. 2. in one of these four cancer markets or are developing groundbreaking new drugs that are being designed to treat not only one of the leading four cancers, but other cancers as well. Key Findings The market for colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. therapies has increased by over seven-fold since 2000. The increase in the value of this market can be explained by new and improved chemotherapeutic agents This is a list of specific pharmacologic agents that are known to be of use in the treatment of cancer, otherwise known as chemotherapeutic agents. This list is organized by "type" of agent, though the subsections are not necessarily definitive and are subject to revision. now on the market, the introduction of key biologic therapies, and improved chemotherapeutic regimens which take into account various new options. The value of the prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. therapy market is over $2.6 billion in 2005. Hormone therapies continue to dominate the market, as they have proven to be the most effective at treating later-stage prostate cancer and are usually second in line to radiation therapy for patients with locally-advanced disease. However, with the looming approval of vaccines, angiogenesis inhibitors, and increased use of chemotherapy in metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. disease, future treatment will take into account the benefits and disadvantages associated with ALL of these therapies. The market for the pharmaceutical treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. is still largely dominated by cytotoxics in 2005-2006, although targeted therapies are beginning to make an impact. Continued uptake of Tarceva and potential approvals for Avastin, Zactima, Erbitux and other new therapies will offset the decline in value that has come as a result of patent expirations in this market. The breast cancer market is the most vibrant and dynamic of the four major cancer markets. Currently, the market is divided between chemotherapeutic agents, anti-hormonals, and Herceptin. The strongest growth in recent years has been in the anti-hormonal sector. The overall value of branded products should increase significantly during the next five years. Uptake of aromatase inhibitors, targeted therapies, and new cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic combinations should increase patient options and result in
increased competition and better clinical outcomes in this dynamic
market.
Topics Covered 1 Methodology and Executive Summary 2 The Global Impact of Cancer 3 Product, Company and Geographic Market Analysis 4 The Colorectal Cancer Therapy Market 5 The Prostate Cancer Therapy Market 6 The Lung Cancer Therapy Market 7 The Breast Cancer Therapy Market 8 Company Briefs Appendices Tables Graphs Diagrams Companies Mentioned Abgenix, Aeterna Zentaris, Amgen, Antigenics, Antisoma, Aphton Corp., AstraZeneca, AVI Biopharma AVI BioPharma Inc. is a medical research and drug development company with corporate offices in Portland, Oregon, United States, and laboratories in Corvallis, Oregon. It was incorporated in 1980. , Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec , Biomira, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were , Celgene, Cell Genesys, Chiron, Dendreon, Eli Lilly Eli Lilly can refer to:
For more information visit http://www.researchandmarkets.com/reports/c29800 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion